Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Gore

Showing results (111-120 of 314) with videos related to

Pageof 32
Sort By:
Pathologie-Biologie|October 1, 1990
Intensive therapy for myelomaT J McElwain, M Meldrum, M E Gore, et al.
BMJ (Clinical Research Ed.)|April 29, 1998
Management of metastatic melanoma during pregnancyS R Johnston, K Broadley, G Henson, et al.
BMJ (Clinical Research Ed.)|May 2, 1998
Commentary: management of the patientS R Johnston, K Broadley, G Henson, et al.
Clinical and Experimental Dermatology|November 28, 2001
Clinico-pathological features of relapsing very thin melanomaL A Fearfield, A Rowe, N Francis, et al.
British Journal of Cancer|March 18, 2004
Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinomaP F Geertsen, M E Gore, S Negrier, et al.
Gut|August 1, 1990
Tumour necrosis factor, cholestatic jaundice, and chronic liver diseaseA Jones, P J Selby, C Viner, et al.
The British Journal of Dermatology|October 17, 2012
Second primary melanomas on treatment with vemurafenib: reply from the authorsL Fearfield, J A Newton-Bishop, R Sinha, et al.
British Journal of Cancer|November 1, 1989
Cisplatin/carboplatin cross-resistance in ovarian cancerM E Gore, I Fryatt, E Wiltshaw, et al.
BJU International|September 4, 2012
Endobronchial metastases from renal cell carcinoma: a late manifestation of the disease with an increasing incidenceMuhammad A Khattak, Rosalie A Fisher, Lisa M Pickering, et al.
The British Journal of Dermatology|August 24, 2012
Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicitiesR Sinha, K Edmonds, J A Newton-Bishop, et al.
Pageof 32

Showing results (111-120 of 314) with videos related to

Sort By:
Pageof 32
Pathologie-Biologie|October 1, 1990
Intensive therapy for myelomaT J McElwain, M Meldrum, M E Gore, et al.
BMJ (Clinical Research Ed.)|April 29, 1998
Management of metastatic melanoma during pregnancyS R Johnston, K Broadley, G Henson, et al.
BMJ (Clinical Research Ed.)|May 2, 1998
Commentary: management of the patientS R Johnston, K Broadley, G Henson, et al.
Clinical and Experimental Dermatology|November 28, 2001
Clinico-pathological features of relapsing very thin melanomaL A Fearfield, A Rowe, N Francis, et al.
British Journal of Cancer|March 18, 2004
Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinomaP F Geertsen, M E Gore, S Negrier, et al.
Gut|August 1, 1990
Tumour necrosis factor, cholestatic jaundice, and chronic liver diseaseA Jones, P J Selby, C Viner, et al.
The British Journal of Dermatology|October 17, 2012
Second primary melanomas on treatment with vemurafenib: reply from the authorsL Fearfield, J A Newton-Bishop, R Sinha, et al.
British Journal of Cancer|November 1, 1989
Cisplatin/carboplatin cross-resistance in ovarian cancerM E Gore, I Fryatt, E Wiltshaw, et al.
BJU International|September 4, 2012
Endobronchial metastases from renal cell carcinoma: a late manifestation of the disease with an increasing incidenceMuhammad A Khattak, Rosalie A Fisher, Lisa M Pickering, et al.
The British Journal of Dermatology|August 24, 2012
Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicitiesR Sinha, K Edmonds, J A Newton-Bishop, et al.
Pageof 32